The stock may react positively to the return to positive Adjusted EBITDA in Q4 and the 2026 guidance, but investors should monitor TriLink's ability to regain CleanCap orders and sustain GMP consumable growth to validate the revenue recovery outlook.
Price Chart
Executive Summary
Maravai LifeSciences reported full-year 2025 revenue of $185.7 million, down 28.3% year-over-year, driven by a 39.0% decline in TriLink segment revenue due to reduced CleanCap orders. The company returned to positive Adjusted EBITDA of $0.5 million in Q4 2025 and provided 2026 guidance of $200-210 million in revenue and $18-20 million in Adjusted EBITDA, signaling operational improvement despite ongoing revenue challenges.
Key Financial Metrics
Key Facts
- Full-year 2025 revenue was $185.7 million, down 28.3% YoY
- TriLink segment revenue fell 39.0% YoY to $119.8 million due to lack of high-volume CleanCap orders
- Cygnus segment revenue grew 5.0% YoY to $66.0 million
- Q4 2025 Adjusted EBITDA turned positive at $0.5 million
- Full-year 2025 Adjusted EBITDA was $(31.2) million
- Company provided 2026 guidance of $200-210 million revenue and $18-20 million Adjusted EBITDA
- Segment names changed: Nucleic Acid Production to TriLink, Biologic Safety Testing to Cygnus
Financial Impact
Revenue declined by $73.4 million (28.3%) in 2025, with TriLink segment down $76.6 million (39.0%)
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| TriLink | $119.8M | -39.0% |
| Cygnus | $66.0M | +5.0% |
Risk Factors
- Continued dependence on volatile CleanCap orders for vaccine programs
- TriLink segment revenue excluding CleanCap still down 8.2% YoY due to lower discovery product demand
- Execution risk in achieving 2026 guidance targets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001823239-26-000005 |
| Document: mrvi-20260225.htm | 0001823239-26-000005 |
| Document: 0001823239-26-000005-index-headers.html | 0001823239-26-000005 |
| Document: 0001823239-26-000005-index.html | 0001823239-26-000005 |
| Document: 0001823239-26-000005.txt | 0001823239-26-000005 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 26d ago | SC 13G | $7.66 | awaiting T+60 | — | $7.51 (−2.02%) |
Jun 14, 2026 19w ago | Institutional Cluster | $4.96 $6.95 | ▲ +40.12% | ▲ +39.12% | $7.51 (+51.31%) |
Jun 3, 2026 20w ago | 8-K | $4.84 $8.37 | ▲ +72.93% | ▲ +70.44% | $7.51 (+55.06%) |
Apr 27, 2026 25w ago | DEFA14A | $3.56 $7.05 | ▲ +98.03% | ▲ +94.04% | $7.51 (+110.81%) |
Feb 26, 2026 34w ago | 8-K | $3.56 $4.40 | ▲ +23.60% | ▲ +15.42% | $7.51 (+110.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers